摘要
目的:观察达格列净(DAP)对2型糖尿病(T2DM)患者心外膜脂肪组织(EAT)体积的影响,并分析EAT体积与血清白细胞介素6(IL-6)和脂联素(ADPN)水平的相关性。方法:测定32例未应用DAP治疗(对照组)和30例应用DAP治疗(DAP治疗组)的T2DM患者的EAT体积,收集两组患者的临床资料并检测血清IL-6和ADPN水平,采用Pearson相关分析EAT体积与IL-6和ADPN水平之间的相关性。结果:与对照组相比,DAP治疗组T2DM患者的EAT体积降低(P<0.01),血清IL-6水平降低(P<0.001),而ADPN水平升高(P<0.001)。EAT体积与T2DM患者血清IL-6含量呈正相关(r=0.509,P<0.01),与血清ADPN含量呈负相关(r=-0.432,P<0.01)。结论:DAP治疗降低T2DM患者的EAT体积,有助于降低心血管事件的发生风险。
Objective:To observe the effect of dapagliflozin(DAP)on the volume of epicardial adipose tissue(EAT)in patients with type 2 diabetes mellitus(T2DM),and analyze the correlation of EAT volume with serum interleukin-6(IL-6)and adiponectin(ADPN)levels.Methods:EAT volume was determined in 32 T2DM patients without DAP therapy(control group)and 30 T2DM patients treated with DAP(DAP group).Clinical data were collected,and serum levels of IL-6 and ADPN were determined in the patients in both groups.Pearson correlation was used to analyze the association between EAT volume and serum IL-6 and ADPN levels.Results:Compared with the control group,the EAT volume and serum IL-6 levels were significantly reduced in T2DM patients treated with DAP(P<0.01),whereas ADPN level was increased(P<0.01).Furthermore,EAT volume was positively correlated with serum IL-6 content in T2DM patients(r=0.509,P<0.01),yet negatively with serum ADPN level(r=-0.432,P<0.01).Conclusion:DAP treatment may reduce EAT volume in patients with T2DM,which can contribute to minimizing the risk of cardiovascular events.
作者
孔祥
王秋云
张翠微
华强
王勇
王德国
KONG Xiang;WANG Qiuyun;ZHANG Cuiwei;HUA Qiang;WANG Yong;WANG Deguo(Department of Endocrinology,The First Affiliated Hospital of Wannan Medical College,Wuhu 241001,Anhui,China)
出处
《皖南医学院学报》
CAS
2024年第3期220-223,共4页
Journal of Wannan Medical College
基金
国家自然科学基金项目(81970699)
安徽省科技厅重点研究与开发计划项目(2022e07020019)。
关键词
2型糖尿病
达格列净
心外膜脂肪组织体积
type 2 diabetes mellitus
dapagliflozin
epicardial adipose tissue volume
